Crystalys Therapeutics Inks $130 Million Series B

Crystalys Therapeutics closed an oversubscribed $130 million Series B financing.

Frazier Life Sciences led the round, with participation from new and existing institutional investors.

Backers included Wellington Management, HBM Healthcare Investments, and Novo Holdings.

The funding gives Crystalys capital to advance its clinical-stage biopharmaceutical programs and reflects investor confidence in its pipeline.